In partial agreement with our data, Esteva et al (2011), in a previous series of 137 metastatic BC, found that PI3K pathway activation (defined as PTEN loss and/or PIK3CA mutation) significantly contributed to worse response to trastuzumab and shorter OS. Here, PTEN is linked to breast cancer.